Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
545 studies found for:    Open Studies | "Leukemia, Myeloid, Acute"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Interventions: Procedure: Tumor sampling;   Biological: Constiutional DNA sampling
2 Recruiting Molecular Imaging to Capture Disease Heterogeneity in Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Intervention: Procedure: FDG-PET/CT guided bone marrow sampling
3 Recruiting A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: CC-90009
4 Recruiting SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: SGI-110 (guadecitabine);   Drug: Treatment Choice
5 Recruiting A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral A-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: AG-120;   Drug: Azacitidine;   Drug: AG-221
6 Recruiting Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: 300 mg Oral Azacitidine;   Drug: Placebo
7 Recruiting A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Azacitidine;   Other: Control Arm
8 Recruiting Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) <= 60y. After First CR
Condition: Leukemia, Myeloid, Acute
Interventions: Biological: Human Stem Cell Transplantation;   Drug: Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
9 Recruiting Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Idarubicin
10 Recruiting A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Decitabine;   Drug: BI 836858
11 Recruiting BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: BI 836858
12 Recruiting A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Cobimetinib;   Drug: Idasanutlin;   Drug: Venetoclax
13 Recruiting A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Biological: PNK-007;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Human recombinant Interleukin-2 (rhIL-2)
14 Not yet recruiting A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Volasertib
15 Recruiting PreventiOn of DYSbioSis Complications With Autologous Fecal Microbiota Transplantation in acutE myEloid Leukemia Patients Undergoing Intensive Treatment
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Autologous Fecal Microbiota Transplantation
16 Recruiting Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: Azacitadine;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Lenograstim;   Drug: Filgastrim
17 Recruiting Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Relapsed Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Intervention: Drug: cabozantinib
18 Not yet recruiting Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Biological: NK Cells + Chemotherapy Starting
19 Not yet recruiting Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: guadecitabine;   Drug: Treatment Choice (TC)
20 Recruiting Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
Condition: Acute Myelogenous Leukemia
Intervention: Drug: Interleukin-2

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.